Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib monosuccinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib monosuccinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. |
ターゲット&IC50 | Syk:9.5 nM |
別名 | GS-9876 monosuccinate |
分子量 | 561.59 |
分子式 | C27H31N9O5 |
CAS No. | 1800046-97-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (222.58 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lanraplenib monosuccinate 1800046-97-2 Angiogenesis Tyrosine Kinase/Adaptors Syk GS 9876 Monosuccinate GS-9876 Monosuccinate GS-9876 monosuccinate Lanraplenib Lanraplenib Monosuccinate GS9876 GS-9876 GS9876 Monosuccinate GS 9876 Inhibitor inhibitor inhibit